+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Acute Lymphoblastic Leukemia Treatment Market Research Report by Types of Cell, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

  • ID: 4857889
  • Report
  • July 2021
  • Region: Global
  • 185 pages
  • 360iResearch™
UP TO OFF
until Sep 30th 2021
The Global Acute Lymphoblastic Leukemia Treatment Market will Grow to USD 3,879.57 Million by 2026, at a CAGR of 6.26%

FEATURED COMPANIES

  • Amgen Inc
  • Calyxt Inc.
  • Erytech Pharma S.A.
  • Genmab A/S
  • Gilead Sciences, Inc.
  • HORIBA, Ltd.
  • MORE
The Global Acute Lymphoblastic Leukemia Treatment Market size was estimated at USD 2,694.18 Million in 2020 and expected to reach USD 2,853.87 Million in 2021, at a Compound Annual Growth Rate (CAGR) 6.26% to reach USD 3,879.57 Million by 2026.



Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Acute Lymphoblastic Leukemia Treatment to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Types of Cell, the Acute Lymphoblastic Leukemia Treatment Market was examined across B-cell ALL, Philadelphia chromosome: Positive (Ph+) and negative (Ph-), and T-cell ALL.
  • Based on Therapy, the Acute Lymphoblastic Leukemia Treatment Market was examined across Chemotherapy, Radiation Therapy, Stem Cell Transplantation, and Targeted Therapy. The Chemotherapy was further studied across CALGB 8811 Regimen, Hyper - CVAD Regimen, Linker Regimen, and Nucleoside Inhibitors.
  • Based on Geography, the Acute Lymphoblastic Leukemia Treatment Market was examined across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas was further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific was further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, and Thailand. The Europe, Middle East & Africa was further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. This ongoing research amplifies this research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Acute Lymphoblastic Leukemia Treatment Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Acute Lymphoblastic Leukemia Treatment Market, including Amgen Inc, Baxter International, Inc., Bio-Techne Corporation, Bristol Myer Squibb Company, Calyxt Inc., Eisai Co Ltd, Erytech Pharma S.A., F. Hoffmann-La Roche AG, Genmab A/S, Genmab AS, Gilead Sciences, Inc., GlaxoSmithKline PLC, HORIBA, Ltd., Jazz Pharmaceuticals PLC, Novartis International AG, Pfizer Inc, Sanofi S.A, Spectrum Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, and Vimeo, LLC.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Acute Lymphoblastic Leukemia Treatment Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Acute Lymphoblastic Leukemia Treatment Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Acute Lymphoblastic Leukemia Treatment Market?
4. What is the competitive strategic window for opportunities in the Global Acute Lymphoblastic Leukemia Treatment Market?
5. What are the technology trends and regulatory frameworks in the Global Acute Lymphoblastic Leukemia Treatment Market?
6. What is the market share of the leading vendors in the Global Acute Lymphoblastic Leukemia Treatment Market?
7. What modes and strategic moves are considered suitable for entering the Global Acute Lymphoblastic Leukemia Treatment Market?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Amgen Inc
  • Calyxt Inc.
  • Erytech Pharma S.A.
  • Genmab A/S
  • Gilead Sciences, Inc.
  • HORIBA, Ltd.
  • MORE
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
3.1. Introduction
3.2. Market Outlook
3.3. Types of Cell Outlook
3.4. Therapy Outlook
3.5. Geography Outlook
3.6. Competitor Outlook

4. Market Overview
4.1. Introduction
4.2. Cumulative Impact of COVID-19

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of acute lymphoblastic leukemia
5.1.1.2. Increasing cancer awareness programs and strong product pipeline
5.1.1.3. Rising R&D activities for the innovation of novel therapies
5.1.1.4. Advancement in molecular biology and pharmacology for development of novel drugs
5.1.2. Restraints
5.1.2.1. High cost of treatment
5.1.3. Opportunities
5.1.3.1. Rising awareness programs for acute lymphoblastic leukemia treatment
5.1.3.2. Growing in healthcare expenditure
5.1.3.3. Increase investment in the R&D of different leukemia
5.1.4. Challenges
5.1.4.1. Stringent regulatory policies
5.1.4.2. Adverse effects associated with the treatment, and complications with chemotherapy
5.2. Porters Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Threat of Substitutes
5.2.3. Bargaining Power of Customers
5.2.4. Bargaining Power of Suppliers
5.2.5. Industry Rivalry

6. Acute Lymphoblastic Leukemia Treatment Market, by Types of Cell
6.1. Introduction
6.2. B-cell ALL
6.3. Philadelphia chromosome: Positive (Ph+) and negative (Ph-)
6.4. T-cell ALL

7. Acute Lymphoblastic Leukemia Treatment Market, by Therapy
7.1. Introduction
7.2. Chemotherapy
7.2.1. CALGB 8811 Regimen
7.2.2. Hyper - CVAD Regimen
7.2.3. Linker Regimen
7.2.4. Nucleoside Inhibitors
7.3. Radiation Therapy
7.4. Stem Cell Transplantation
7.5. Targeted Therapy

8. Americas Acute Lymphoblastic Leukemia Treatment Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States

9. Asia-Pacific Acute Lymphoblastic Leukemia Treatment Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Thailand

10. Europe, Middle East & Africa Acute Lymphoblastic Leukemia Treatment Market
10.1. Introduction
10.2. France
10.3. Germany
10.4. Italy
10.5. Netherlands
10.6. Qatar
10.7. Russia
10.8. Saudi Arabia
10.9. South Africa
10.10. Spain
10.11. United Arab Emirates
10.12. United Kingdom

11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis
11.3. Market Share Analysis, By Key Player
11.4. Competitive Scenario
11.4.1. Merger & Acquisition
11.4.2. Agreement, Collaboration, & Partnership
11.4.3. New Product Launch & Enhancement
11.4.4. Investment & Funding
11.4.5. Award, Recognition, & Expansion

12. Company Usability Profiles
12.1. Amgen Inc
12.2. Baxter International, Inc.
12.3. Bio-Techne Corporation
12.4. Bristol Myer Squibb Company
12.5. Calyxt Inc.
12.6. Eisai Co Ltd
12.7. Erytech Pharma S.A.
12.8. F. Hoffmann-La Roche AG
12.9. Genmab A/S
12.10. Genmab AS
12.11. Gilead Sciences, Inc.
12.12. GlaxoSmithKline PLC
12.13. HORIBA, Ltd.
12.14. Jazz Pharmaceuticals PLC
12.15. Novartis International AG
12.16. Pfizer Inc
12.17. Sanofi S.A
12.18. Spectrum Pharmaceuticals, Inc.
12.19. Takeda Pharmaceutical Company Limited
12.20. Vimeo, LLC

13. Appendix
13.1. Discussion Guide
13.2. License & Pricing

List of Figures
FIGURE 1. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, 2020 VS 2026 (USD MILLION)
FIGURE 2. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY TYPES OF CELL, 2020 (USD MILLION)
FIGURE 3. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY THERAPY, 2020 (USD MILLION)
FIGURE 4. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)
FIGURE 5. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 6. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET: MARKET DYNAMICS
FIGURE 7. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET: PORTERS FIVE FORCES ANALYSIS
FIGURE 8. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY TYPES OF CELL, 2020 VS 2026 (%)
FIGURE 9. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY TYPES OF CELL, 2020 VS 2026 (USD MILLION)
FIGURE 10. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY TYPES OF CELL, 2026
FIGURE 11. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY B-CELL ALL, 2018-2026 (USD MILLION)
FIGURE 12. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY B-CELL ALL, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
FIGURE 13. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY PHILADELPHIA CHROMOSOME: POSITIVE (PH+) AND NEGATIVE (PH-), 2018-2026 (USD MILLION)
FIGURE 14. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY PHILADELPHIA CHROMOSOME: POSITIVE (PH+) AND NEGATIVE (PH-), BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
FIGURE 15. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY T-CELL ALL, 2018-2026 (USD MILLION)
FIGURE 16. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY T-CELL ALL, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
FIGURE 17. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY THERAPY, 2020 VS 2026 (%)
FIGURE 18. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY THERAPY, 2020 VS 2026 (USD MILLION)
FIGURE 19. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY THERAPY, 2026
FIGURE 20. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2026 (USD MILLION)
FIGURE 21. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
FIGURE 22. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY CALGB 8811 REGIMEN, 2018-2026 (USD MILLION)
FIGURE 23. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY CALGB 8811 REGIMEN, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
FIGURE 24. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY HYPER - CVAD REGIMEN, 2018-2026 (USD MILLION)
FIGURE 25. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY HYPER - CVAD REGIMEN, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
FIGURE 26. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY LINKER REGIMEN, 2018-2026 (USD MILLION)
FIGURE 27. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY LINKER REGIMEN, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
FIGURE 28. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY NUCLEOSIDE INHIBITORS, 2018-2026 (USD MILLION)
FIGURE 29. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY NUCLEOSIDE INHIBITORS, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
FIGURE 30. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY RADIATION THERAPY, 2018-2026 (USD MILLION)
FIGURE 31. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
FIGURE 32. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANTATION, 2018-2026 (USD MILLION)
FIGURE 33. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
FIGURE 34. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2026 (USD MILLION)
FIGURE 35. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
FIGURE 36. AMERICAS ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
FIGURE 37. AMERICAS ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
FIGURE 38. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2026
FIGURE 39. ARGENTINA ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 40. BRAZIL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 41. CANADA ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 42. MEXICO ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 43. UNITED STATES ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 44. ASIA-PACIFIC ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
FIGURE 45. ASIA-PACIFIC ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
FIGURE 46. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2026
FIGURE 47. AUSTRALIA ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 48. CHINA ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 49. INDIA ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 50. INDONESIA ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 51. JAPAN ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 52. MALAYSIA ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 53. PHILIPPINES ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 54. SINGAPORE ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 55. SOUTH KOREA ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 56. THAILAND ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 57. EUROPE, MIDDLE EAST & AFRICA ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
FIGURE 58. EUROPE, MIDDLE EAST & AFRICA ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
FIGURE 59. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2026
FIGURE 60. FRANCE ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 61. GERMANY ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 62. ITALY ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 63. NETHERLANDS ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 64. QATAR ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 65. RUSSIA ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 66. SAUDI ARABIA ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 67. SOUTH AFRICA ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 68. SPAIN ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 69. UNITED ARAB EMIRATES ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 70. UNITED KINGDOM ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 71. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET: FPNV POSITIONING MATRIX
FIGURE 72. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET: SHARE, BY KEY PLAYER, 2020
FIGURE 73. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET, BY TYPE

List of Tables
TABLE 1. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 4. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY TYPES OF CELL, 2018-2026 (USD MILLION)
TABLE 5. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY B-CELL ALL, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 6. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY PHILADELPHIA CHROMOSOME: POSITIVE (PH+) AND NEGATIVE (PH-), BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 7. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY T-CELL ALL, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 8. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2026 (USD MILLION)
TABLE 9. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 10. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY CALGB 8811 REGIMEN, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 11. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY HYPER - CVAD REGIMEN, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 12. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY LINKER REGIMEN, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 13. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY NUCLEOSIDE INHIBITORS, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 14. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 15. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 16. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 17. AMERICAS ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 18. AMERICAS ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY TYPES OF CELL, 2018-2026 (USD MILLION)
TABLE 19. AMERICAS ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2026 (USD MILLION)
TABLE 20. ARGENTINA ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY TYPES OF CELL, 2018-2026 (USD MILLION)
TABLE 21. ARGENTINA ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2026 (USD MILLION)
TABLE 22. BRAZIL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY TYPES OF CELL, 2018-2026 (USD MILLION)
TABLE 23. BRAZIL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2026 (USD MILLION)
TABLE 24. CANADA ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY TYPES OF CELL, 2018-2026 (USD MILLION)
TABLE 25. CANADA ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2026 (USD MILLION)
TABLE 26. MEXICO ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY TYPES OF CELL, 2018-2026 (USD MILLION)
TABLE 27. MEXICO ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2026 (USD MILLION)
TABLE 28. UNITED STATES ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 29. UNITED STATES ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY TYPES OF CELL, 2018-2026 (USD MILLION)
TABLE 30. UNITED STATES ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2026 (USD MILLION)
TABLE 31. ASIA-PACIFIC ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 32. ASIA-PACIFIC ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY TYPES OF CELL, 2018-2026 (USD MILLION)
TABLE 33. ASIA-PACIFIC ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2026 (USD MILLION)
TABLE 34. AUSTRALIA ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY TYPES OF CELL, 2018-2026 (USD MILLION)
TABLE 35. AUSTRALIA ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2026 (USD MILLION)
TABLE 36. CHINA ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY TYPES OF CELL, 2018-2026 (USD MILLION)
TABLE 37. CHINA ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2026 (USD MILLION)
TABLE 38. INDIA ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY TYPES OF CELL, 2018-2026 (USD MILLION)
TABLE 39. INDIA ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2026 (USD MILLION)
TABLE 40. INDONESIA ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY TYPES OF CELL, 2018-2026 (USD MILLION)
TABLE 41. INDONESIA ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2026 (USD MILLION)
TABLE 42. JAPAN ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY TYPES OF CELL, 2018-2026 (USD MILLION)
TABLE 43. JAPAN ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2026 (USD MILLION)
TABLE 44. MALAYSIA ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY TYPES OF CELL, 2018-2026 (USD MILLION)
TABLE 45. MALAYSIA ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2026 (USD MILLION)
TABLE 46. PHILIPPINES ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY TYPES OF CELL, 2018-2026 (USD MILLION)
TABLE 47. PHILIPPINES ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2026 (USD MILLION)
TABLE 48. SINGAPORE ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY TYPES OF CELL, 2018-2026 (USD MILLION)
TABLE 49. SINGAPORE ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2026 (USD MILLION)
TABLE 50. SOUTH KOREA ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY TYPES OF CELL, 2018-2026 (USD MILLION)
TABLE 51. SOUTH KOREA ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2026 (USD MILLION)
TABLE 52. THAILAND ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY TYPES OF CELL, 2018-2026 (USD MILLION)
TABLE 53. THAILAND ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2026 (USD MILLION)
TABLE 54. EUROPE, MIDDLE EAST & AFRICA ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 55. EUROPE, MIDDLE EAST & AFRICA ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY TYPES OF CELL, 2018-2026 (USD MILLION)
TABLE 56. EUROPE, MIDDLE EAST & AFRICA ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2026 (USD MILLION)
TABLE 57. FRANCE ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY TYPES OF CELL, 2018-2026 (USD MILLION)
TABLE 58. FRANCE ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2026 (USD MILLION)
TABLE 59. GERMANY ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY TYPES OF CELL, 2018-2026 (USD MILLION)
TABLE 60. GERMANY ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2026 (USD MILLION)
TABLE 61. ITALY ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY TYPES OF CELL, 2018-2026 (USD MILLION)
TABLE 62. ITALY ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2026 (USD MILLION)
TABLE 63. NETHERLANDS ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY TYPES OF CELL, 2018-2026 (USD MILLION)
TABLE 64. NETHERLANDS ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2026 (USD MILLION)
TABLE 65. QATAR ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY TYPES OF CELL, 2018-2026 (USD MILLION)
TABLE 66. QATAR ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2026 (USD MILLION)
TABLE 67. RUSSIA ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY TYPES OF CELL, 2018-2026 (USD MILLION)
TABLE 68. RUSSIA ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2026 (USD MILLION)
TABLE 69. SAUDI ARABIA ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY TYPES OF CELL, 2018-2026 (USD MILLION)
TABLE 70. SAUDI ARABIA ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2026 (USD MILLION)
TABLE 71. SOUTH AFRICA ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY TYPES OF CELL, 2018-2026 (USD MILLION)
TABLE 72. SOUTH AFRICA ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2026 (USD MILLION)
TABLE 73. SPAIN ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY TYPES OF CELL, 2018-2026 (USD MILLION)
TABLE 74. SPAIN ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2026 (USD MILLION)
TABLE 75. UNITED ARAB EMIRATES ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY TYPES OF CELL, 2018-2026 (USD MILLION)
TABLE 76. UNITED ARAB EMIRATES ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2026 (USD MILLION)
TABLE 77. UNITED KINGDOM ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY TYPES OF CELL, 2018-2026 (USD MILLION)
TABLE 78. UNITED KINGDOM ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2026 (USD MILLION)
TABLE 79. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET: SCORES
TABLE 80. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET: BUSINESS STRATEGY
TABLE 81. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET: PRODUCT SATISFACTION
TABLE 82. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET: RANKING
TABLE 83. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET: SHARE, BY KEY PLAYER, 2020
TABLE 84. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET: MERGER & ACQUISITION
TABLE 85. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 86. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 87. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET: INVESTMENT & FUNDING
TABLE 88. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 89. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT MARKET: LICENSE & PRICING
Note: Product cover images may vary from those shown
  • Amgen Inc
  • Baxter International, Inc.
  • Bio-Techne Corporation
  • Bristol Myer Squibb Company
  • Calyxt Inc.
  • Eisai Co Ltd
  • Erytech Pharma S.A.
  • F. Hoffmann-La Roche AG
  • Genmab A/S
  • Genmab AS
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • HORIBA, Ltd.
  • Jazz Pharmaceuticals PLC
  • Novartis International AG
  • Pfizer Inc
  • Sanofi S.A
  • Spectrum Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited
  • Vimeo, LLC
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll